BNP Measurement Reduces Resource Utilization for Patients With CHF Admitted Thorough the ED
1 other identifier
observational
200
1 country
1
Brief Summary
Measurement of brain natriuretic peptide (BNP) in dyspneic patients increases diagnostic accuracy for congestive heart failure (CHF). Limited information is available regarding economic outcomes attributable to BNP assay. The aim of this study was to assess the economic impact of BNP assay in elderly dyspneic patients presenting to the emergency department (ED).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2003
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2005
CompletedFirst Submitted
Initial submission to the registry
December 26, 2007
CompletedFirst Posted
Study publicly available on registry
January 8, 2008
CompletedJanuary 8, 2008
December 1, 2007
1.2 years
December 26, 2007
December 26, 2007
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mean total hospital cost per subject
spans from ED eval through hospitalization discharge
Secondary Outcomes (1)
Included admission rate, service assignment, discharge diagnosis, and length of stay.
from ED evaluation through hospitalization discharge
Study Arms (2)
A
BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
B
BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
Eligibility Criteria
Dyspneic patients:65 years or older presenting to the ED with chief complaint of shortness of breath, were enrolled in a randomized, controlled trial.
You may qualify if:
- Dyspneic patients 65 years or older presenting to the ED with chief complaint of shortness of breath.
You may not qualify if:
- hemodynamically unstability
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Saint Marys Hospital, Mayo Clinic
Rochester, Minnesota, 55905, United States
Related Publications (2)
Schmidt TA, Salo D, Hughes JA, Abbott JT, Geiderman JM, Johnson CX, McClure KB, McKay MP, Razzak JA, Schears RM, Solomon RC; SAEM Ethics Committee. Confronting the ethical challenges to informed consent in emergency medicine research. Acad Emerg Med. 2004 Oct;11(10):1082-9. doi: 10.1197/j.aem.2004.05.028.
PMID: 15466152BACKGROUNDClavell AL, Stingo AJ, Aarhus LL, Burnett JC Jr. Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction. Am J Physiol. 1993 Dec;265(6 Pt 2):R1416-22. doi: 10.1152/ajpregu.1993.265.6.R1416.
PMID: 8285286BACKGROUND
Biospecimen
Original protocol specifies a single 10 ml of blood is collected and frozen from each study participant (N=200), to be available for research assays.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Raquel M Schears, MD, MPH
Mayo Clinic
- PRINCIPAL INVESTIGATOR
Alfredo L Clavell, MD
Mayo Clinic
- STUDY CHAIR
Lyle J Olsen, MD
Mayo Clinic
- STUDY DIRECTOR
Paula J Santrach, MD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 26, 2007
First Posted
January 8, 2008
Study Start
December 1, 2003
Primary Completion
March 1, 2005
Study Completion
March 1, 2005
Last Updated
January 8, 2008
Record last verified: 2007-12